With extensive ongoing development in personalized medicines and the application of biomarkers in diagnosis, the complexity of the central nervous system paves way for the development of biomarkers to enhance early diagnosis of neurological disorders such as Alzheimer's disease, Parkinson's disease, multiple sclerosis, and other neurological conditions.
This report contains market size and forecasts of Central Nervous System Biomarkers in Global, including the following market information:
- Global Central Nervous System Biomarkers Market Revenue, 2017-2022, 2023-2028, ($ millions)
- Global top five companies in 2021 (%)
The global Central Nervous System Biomarkers market was valued at 3974.4 million in 2021 and is projected to reach US$ 5837.8 million by 2028, at a CAGR of 5.6% during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Safety Biomarker Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Central Nervous System Biomarkers include Merck, Takeda Pharmaceutical, Thermo Fisher Scientific, Avacta Group, Diagenic Asa, Banyan Biomarkers, Eli Lilly, Pfizer and Alseres Pharmaceuticals, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
We surveyed the Central Nervous System Biomarkers companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Central Nervous System Biomarkers Market, by Type, 2017-2022, 2023-2028 ($ millions)
Global Central Nervous System Biomarkers Market Segment Percentages, by Type, 2021 (%)
- Safety Biomarker
- Efficacy Biomarker
- Validation Biomarker
- Other
Global Central Nervous System Biomarkers Market, by Application, 2017-2022, 2023-2028 ($ millions)
Global Central Nervous System Biomarkers Market Segment Percentages, by Application, 2021 (%)
Global Central Nervous System Biomarkers Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)
Global Central Nervous System Biomarkers Market Segment Percentages, By Region and Country, 2021 (%)
- North America
- US
- Canada
- Mexico
- Europe
- Germany
- France
- U.K.
- Italy
- Russia
- Nordic Countries
- Benelux
- Rest of Europe
- Asia
- China
- Japan
- South Korea
- Southeast Asia
- India
- Rest of Asia
- South America
- Brazil
- Argentina
- Rest of South America
- Middle East & Africa
- Turkey
- Israel
- Saudi Arabia
- UAE
- Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
- Key companies Central Nervous System Biomarkers revenues in global market, 2017-2022 (estimated), ($ millions)
- Key companies Central Nervous System Biomarkers revenues share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
- Merck
- Takeda Pharmaceutical
- Thermo Fisher Scientific
- Avacta Group
- Diagenic Asa
- Banyan Biomarkers
- Eli Lilly
- Pfizer
- Alseres Pharmaceuticals
- Acumen pharmaceuticals
- EKF Diagnostics
- Abiant
- Myriad RBM
- Aposense
